Study of the Clinical Benefits of Different Formulations of Amphotericin B

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06123832

Enrollment

184

Registered

2023-11-09

Start date

2023-09-01

Completion date

2024-12-31

Last updated

2024-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Efficacy, Safety

Keywords

Liposomal Amphotericin B for Injection, Amphotericin B Cholesteryl Sulfate Complex for Injection, Amphotericin B for Injection, Safety, Efficacy

Brief summary

This project intends to carry out a multi-center retrospective observational real-world study to understand the current status of amphotericin B use by formulation type, compare the differences in safety and efficacy of each formulation in domestic clinical application, provide real-world evidence for clinical drug selection, and provide evidence-based evidence in support of rational clinical drug use.

Detailed description

The researchers selected patients with amphotericin B use records discharged from five tertiary hospitals across the country from January 1, 2020 to the present, extracted data according to the inclusion and exclusion criteria, and divided them into experimental and control groups, in order to understand the current status of amphotericin B use in each preparation type, compare the differences in the safety and efficacy of the various preparations in the domestic clinical application, and provide real-world evidence of the choice of clinical medication.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. Patients discharged from January 1, 2020 to the present; 2. Patients with a record of amphotericin B use.

Exclusion criteria

1.Key information missing from patient studies.

Design outcomes

Primary

Measure	Time frame	Description
Overall Adverse Reaction Rate	Through study completion,up to half a year.	The incidence of total adverse reactions was analyzed to assess the difference in safety of amphotericin B by formulation type in domestic clinical application, to provide real-world evidence for clinical drug selection, and to provide evidence-based evidence in support of rational clinical drug use.
Pathogen clearance rate	Through study completion,up to half a year.	To assess the differences in effectiveness of amphotericin B by formulation type in domestic clinical application by analyzing the pathogen clearance rate, to provide real-world evidence for clinical dosing selection, and to provide evidence-based evidence to support rational clinical dosing.

Countries

China

Outcome results